Table 1 Characteristics of patients at the time of fractionated stereotactic radiotherapy (n = 73)
From: Fractionated stereotactic radiotherapy of brain metastases: results of a retrospective study
Characteristics | Value |
|---|---|
Patient age, years, median (Interquartile range, IQR) | 61.0 (51.0, 67.5) |
Sex, n (%) | |
Men | 40 (54.8%) |
Women | 33 (45.2%) |
Primary cancer, n (%) | |
Malignant melanoma | 25 (34.2%) |
NSCLC adenocarcinoma | 19 (26.0%) |
NSCLC non-adenocarcinoma | 7 (9.6%) |
Breast cancer | 6 (8.2%) |
Gastrointestinal carcinoma | 5 (6.8%) |
Renal cell carcinoma | 1 (1.4%) |
Other | 10 (13.7%) |
Initial UICC stage, n (%) | |
I | 8 (10.9%) |
II | 8 (10.9%) |
III | 15 (20.5%) |
IV | 38 (52.0%) |
Unknown/Missing | 4 (5.5%) |
Karnofsky performance score, median (IQR) | 70 (65, 90) |
Systemic treatment * 3 months before/after fractionated stereotactic radiotherapy, n (%) | 66 (90.4%) |
Number of brain metastases treated with 6x5Gy, median (IQR) | 1.0 (1.0, 2.0) |
Recursive partitioning analysis (RPA), median (IQR) | 2.0 (2.0, 2.5) |
Recursive partitioning analysis (RPA), RPA class, n (%) | |
1 | 13 (17.8%) |
2 | 42 (57.5%) |
3 | 18 (24.7%) |
Diagnosis-specific graded prognostic assessment (ds-GPA), median (IQR) | 1.5 (1.0, 2.5) |
Diagnosis-specific graded prognostic assessment (ds-GPA), groups | |
0–1.0 | 21 (28.8%) |
1.5–2.0 | 30 (41.1%) |
2.5–3.0 | 21 (28.8%) |
3.5–4.0 | 1 (1.4%) |
Disease control of the primary cancer, n (%) | |
Yes | 53 (72.6%) |
No | 11 (15.1%) |
Missing/Unknown | 9 (12.3%) |
Extracranial metastases, n (%) | |
Yes | 48 (65.8%) |
No | 25 (34.2%) |